Evogene (EVGN) Net Income towards Common Stockholders (2012 - 2026)
Evogene (EVGN) posted Net Income towards Common Stockholders of -$5.9 million for Q1 2026, down 10.57% sequentially from -$5.3 million in Q4 2025, and down 126.9% YoY from $21.8 million in Q1 2025.
Evogene (EVGN) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Evogene has reported Net Income towards Common Stockholders for 15 years, with the latest figure at -$5.9 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 126.9% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 169.21% YoY) and the FY2025 annual result came in at -$8.5 million, up 48.53% from the prior year.
- Net Income towards Common Stockholders retreated to -$5.9 million in Q1 2026 per EVGN's latest filing, from -$5.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $8.8 million in Q2 2022 and troughed at -$8.3 million in Q1 2022.
- A 5-year average of -$2.3 million and a median of -$4.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders soared 242.05% in 2022, then slumped 1343.33% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$3.0 million in 2022, then slumped by 120.18% to -$6.6 million in 2023, then jumped by 106.47% to $427000.0 in 2024, then plunged by 1343.33% to -$5.3 million in 2025, then fell by 10.57% to -$5.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$5.9 million, -$5.3 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -5.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.87 Mn |
| Dec 31, 2025 | -5.31 Mn |
| Sep 30, 2025 | 3.87 Mn |
| Jun 30, 2025 | -4.46 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | 427,000.00 |
| Sep 30, 2024 | -7.63 Mn |
| Jun 30, 2024 | 5.42 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -6.60 Mn |
| Sep 30, 2023 | -3.98 Mn |
| Jun 30, 2023 | 7.02 Mn |
| Mar 31, 2023 | -6.27 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -6.54 Mn |
| Jun 30, 2022 | 8.82 Mn |
| Mar 31, 2022 | -8.28 Mn |
| Dec 31, 2021 | -7.37 Mn |
| Sep 30, 2021 | -7.61 Mn |
| Jun 30, 2021 | -6.21 Mn |